ArticleNature2020
B cells are associated with survival and immunotherapy response in sarcoma.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,268 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,268citing papers in PubMed, 2 pooled it
159.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,268 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,848 citations in OpenAlex.
- Epstein-Barr virus-driven immunosuppression in nasopharyngeal carcinoma: a comprehensive review of viral mechanisms, spatial tumor ecosystems, and precision therapeutics.Frontiers in immunology · 2026Pooled it
- Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines.Cancers · 2025Guideline
- Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses.Journal for immunotherapy of cancer · 2026Trial
- Trial
- Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.British journal of cancer · 2026Trial
- Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial.Frontiers in immunology · 2026Trial
- Sintilimab plus Anlotinib in Patients with Pretreated Locally Advanced or Metastatic Sarcoma: A Prospective, Single-Arm, Phase II Clinical Trial.Cancer immunology research · 2025Trial
- Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.Nature communications · 2025Trial
- Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity.Journal for immunotherapy of cancer · 2025Trial
- Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Efineptakin alfa (NT-I7) improves overall survival and induces immune niches in murine tumors.Genes & diseases · 2027Article
- Broad targeting of HPV E proteins by intratumoral and systemic B cell responses in HPV+ head and neck cancer.Oncoimmunology · 2026Article
- The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions.Human vaccines & immunotherapeutics · 2026Review
- Circular RNAs in tumorigenesis: an insight into recent research in biogenesis and targeted tumor therapy.Cell cycle (Georgetown, Tex.) · 2026Review
- Tertiary lymphoid structures in gastrointestinal cancer: orchestrating tumour microenvironmental immune subcycles to elegantly amplify the cancer immunity cycle.Annals of medicine · 2026Review
- Neutrophil-epithelial niches arrest B-cell maturation in dysfunctional tertiary lymphoid structures of gastric cancer neoadjuvant immunochemotherapy.Journal for immunotherapy of cancer · 2026Article
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- Targeting the DNA Damage Response in Cancer.MedComm · 2026Review
1,208 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
29 authors at 15 institutions in 3 countries.
Florent PetitprezTeam Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.
Aurélien de Reyniès *Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France.
Emily Z Keung *Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tom Wei-Wu ChenGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
Cheng-Ming SunTeam Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.
Julien CalderaroTeam Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.
Yung-Ming JengCenters of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan.
Li-Ping HsiaoDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Laetitia LacroixTeam Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.
Antoine BougoüinTeam Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.
Marco MoreiraTeam Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.
Guillaume LacroixTeam Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.
Ivo NatarioTeam Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.
Julien AdamDepartment of Biology and Pathology, Gustave Roussy, Villejuif, France.
Carlo LucchesiInstitut Bergonié, Bordeaux, France.
Yec Han LaizetInstitut Bergonié, Bordeaux, France.
Maud ToulmondeInstitut Bergonié, Bordeaux, France.
Melissa A BurgessDepartment of Medicine, Divison of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA, USA.
Vanessa BolejackCancer Research and Biostatistics, Seattle, WA, USA.
Denise ReinkeSarcoma Alliance for Research Through Collaboration, Ann Arbor, MI, USA.
Khalid M WaniDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wei-Lien WangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alexander J LazarDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christina L RolandDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer A WargoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Antoine ItalianoInstitut Bergonié, Bordeaux, France.
Catherine Sautès-FridmanTeam Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.
Hussein A TawbiDepartment of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. htawbi@mdanderson.org.
Wolf H FridmanTeam Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France. herve.fridman@crc.jussieu.fr.
The University of Texas MD Anderson Cancer Center · USCentre de Recherche des Cordeliers · FRInstitut Bergonié · FRNational Taiwan University Hospital · TWSorbonne Paris Cité · FRSorbonne Université · FRUniversité Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FRCancer Research And Biostatistics · USInstitut Gustave Roussy · FRLa Ligue Contre le Cancer · FRNational Taiwan University · TWSarcoma Alliance for Research through Collaboration · USUniversité de Bordeaux · FRUniversity of Pittsburgh · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTRAINING OF ACADEMIC SURGICAL ONCOLOGISTST32CA009599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Ashley M Holder, Jennifer A. Wargo · 1988 to 2026
$13.2MNCI NIH HHS T32 CA009599
Abstract
Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes
Indexed as
ImmunotherapyAntibodies, Monoclonal, HumanizedB-LymphocytesCD8-Positive T-LymphocytesCohort StudiesDendritic Cells, FollicularHumansMutationPhenotypePrognosisProgrammed Cell Death 1 ReceptorReproducibility of ResultsSarcomaSurvival RateTertiary Lymphoid StructuresTumor MicroenvironmentAntibodies, Monoclonal, HumanizedPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.